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Abbreviations {#nc005}
=============

ACLS

:   advanced cardiac life support

ATP

:   anti-tachycardia pacing

CA

:   catheter ablation

ES

:   electrical storm

ICD

:   implantable cardioverter defibrillator

ICM

:   Ischemic Cardiomyopathy

IV

:   intravenous

NIDCM

:   non-ischemic dilated cardiomyopathy

VF

:   ventricular fibrillation

VT

:   ventricular tachycardia

1. Introduction {#s0005}
===============

The most widely used definition of ventricular tachycardia (VT) is three or more consecutive ventricular beats, at a rate \>100 per minute [@b0005]. It is classified based on hemodynamic stability, duration (nonsustained if \<30 seconds and sustained if \>30 seconds or requiring termination due to hemodynamic compromise in \<30 seconds), morphology (monomorphic or polymorphic, etc.) or mechanism (scar-related re-entry, automaticity, and triggered activity) [@b0010]. Of all the VTs, 10% occurs in those with structurally normal heart and these are referred to as idiopathic VTs, and the remaining 90% occurs in patients with structural heart disease [@b0010]. Incessant VT is defined as hemodynamically stable VT which persists for longer than 12 hours [@b0015] ES in those without ICD is referred to three or more sustained VT or ventricular fibrillation (VF) occurring within 24 hours [@b0005], [@b0020]. In patient with an ICD is best defined as three appropriate VT detections in 24 hours, treated by antitachycardia pacing (ATP), shock, or eventually untreated but sustained in a VT monitoring zone [@b0025].

2. Incidence and risk factors {#s0010}
=============================

According to the above -mentioned definition of ES, the incidence is ∼10--20% in patients who have an ICD implanted for secondary prevention of sudden cardiac death [@b0030], [@b0035]. It is lower when ICDs are implanted for primary prevention with an incidence of 4% [@b0040]. Monomorphic VT is the most common form of ES with an incidence of 86--97% [@b0045]. The most common causes of ES include electrolytes (hypo- and hyperkalemia) and metabolic imbalance, myocardial ischemia and infarction, drug-induced proarrhythmia, inherited channelopathies (such as Brugada syndrome), and congestive heart failure [@b0050]. Other risk factors for ES include advanced age, male sex, a low left ventricular ejection fraction, and New York Heart Association functional Class III or IV heart failure, antiarrhythmic agents, hypomagnesemia, hyperthyroidism, and infection or fever [@b0055]. Vicent et al. [@b0060] recently reported six of 108 patients who received sacubitril/valsartan for heart failure with reduced ejection fraction, developed ventricular electrical storm. They concluded that their data are not enough to infer a cause and effect relationship but further investigations are needed to study the proarrhythmic effect of sacubitril/valsartan.

3. Prognosis {#s0015}
============

ES is a life-threatening clinical condition that requires prompt treatment. Eighty percent of the patients are hospitalized especially those who receive a shock from their devices [@b0065]. Moreover, the electrical instability impairs the patient's quality of life [@b0025]. Most studies suggest that ES is an independent adverse prognostic factor [@b0045]. The mortality is as high as 82% [@b0070]. Also increased mortality has been documented in patients experiencing ES in the (AVID), MADIT (Multicenter Automatic Defibrillator Implantation Trial) II trials [@b0030], [@b0040]. In addition, a meta-analysis of 13 studies revealed that ES was associated with a high mortality rate, increased cardiac transplantation, and hospitalization for acute heart failure [@b0075].

4. Mechanism {#s0020}
============

The most common mechanism of sustained ventricular arrythmia in structural heart disease is re-entry [@b0005]. Most monomorphic VTs are due to re-entry mechanism. The structural cardiac changes after an acute myocardial infarction or progresses of nonischemic cardiomyopathy (NICM), lead to scar formation as a consequence to fibrosis [@b0055]. Epicardial patchy fibrosis and abnormal conduction may be detected in 30--50% of patients with NICM [@b0080]. The scar then creates a fixed anatomic barrier to electrical conduction. The survived myofibrils around the border of the scar provide a slow pathway for electrically stable re-entry. A harmless trigger such as premature ventricular ectopic, can initiate monomorphic VT [@b0055].

5. Acute management {#s0025}
===================

The management starts with proper diagnosis of the ventricular arrhythmia. VT should be differentiated from other resembling conditions such as bundle branch block, ventricular preexcitation (Wolff--Parkinson--White syndrome), or supraventricular tachycardia with aberrancy. An undifferentiated wide-complex tachycardia should be treated as VT, particularly in patients who have structural heart disease [@b0055]. Patients with ES should be evaluated immediately for hemodynamic instability and should be treated according to advanced cardiac life support (ACLS) [@b0085]. An algorithm for acute management of ES is suggested in [Fig. 1](#f0005){ref-type="fig"} [@b0090]. Those with VT storm, having pulse and are hemodynamically unstable should receive synchronized cardioversion. Patients who have poor systolic function or rapid VT might require multiple electrical cardioversions or defibrillations [@b0055]. The reversible precipitating factors should be treated aggressively ([Table 1](#t0005){ref-type="table"}) [@b0095].Figure 1Acute management algorithm for electrical storm [@b0090]. ACLS = advanced cardiac life support; IV = intravenous.Table 1Reversible causes of electrical storm.Acute myocardial ischemiaElectrolyte imbalancesDecompensated heart failureHyperthyroidismInfections, feverProarrhythmic drug effects earlyPostoperative period

Patients with stable ES and those who received cardioversion due to hemodynamic instability, urgent intravenous (IV) antiarrhythmics drugs, and β-blocker should be started. The recommended approach is IV amiodarone (150 mg IV over 10 minutes, followed by 1 mg/minute IV infusion for 6 hours, followed by 0.5 mg/minute IV infusion for an 18 additional hours). Administration of β-blocker has been shown to improve survival at 1 week and 1 year in ES refractory to amiodarone and/or lidocaine and repeated cardioversions [@b0070]. The preferred β-blocker is propranolol [@b0100], [@b0105] (40 mg every 6 hours for the first 48 hours, with additional IV doses as needed for recurrent breakthrough ventricular arrhythmias) [@b0105].

A summary of pharmacologic and nonpharmacologic therapy for acute management of ES is presented in [Table 2](#t0010){ref-type="table"} [@b0005], [@b0095], [@b0090].Table 2Antiarrhythmic medications for acute and long-term treatment of ES.Acute managementLong-term treatment*β-blockers*PropranololBolus: 0.15 mg/kg IV over 10 min then 40 mg every 6 hours for the first 48 h10--40 mg by mouth 3--4 times a dMetoprololBolus: 5 mg IV every 5 min up to 3 doses25 mg by mouth twice a d up to 200 mg a dEsmololBolus: 0.5 mg/kg IV for 1 min\
Infusion: 0.05 mg/kg/minNot recommended  *Class III agents*AmiodaroneBolus: 150 mg IV over 10 min, up to total 2.2 g in 24 h\
Infusion: 1 mg/min for 6 h, then 0.5 mg/min for 18 hOral load: 800 mg by mouth twice a d until 10 g total\
Maintenance dose: 200--400 mg by mouth daily  Class I agentsLidocaineBolus: 1.0--1.5 mg/kg IV, repeat dose of 0.5--0.75 mg/kg IV up to a total dose of 3 mg/kg\
Infusion:1--4 mg/min although 1 could start at 0.5 mg/minProcainamideBolus: 10 mg/kg IV over 20 min3--6 g by mouth daily fractionated in ≥3 administrationsMexiletineNot recommended200 mg by mouth 3 times a day, up to 400 mg by mouth 3 times a day  *Other treatments*PropofolBolus: 50 mg IV propofol infusion: 100 mcg/kg/minOverdrive pacingStart at 90 bpm & titrate upward as needed, usually not faster than 110 bpm[^1]

Early and aggressive use of analgesics and sedative drugs should be considered in patients with ICD who received multiple shocks. Combination of benzodiazepines such as midazolam and short-acting analgesics such as remifentanil provide analgesia without negative inotropic effects. Remifentanil at infusion rate 0.06--0.12 μg/kg/min with intermittent boluses of midazolam were used and the patient expressed no discomfort with the external cardioversions [@b0110]. Propofol is a short acting general anesthetic agent that acts through its interactions with the gamma-aminobutyric acid receptor [@b0115], [@b0120]. The used bolus doses and infusion rate of propofol that terminated the ventricular arrythmias were 20--40 mg iv and 40--50 μg/kg/min, respectively [@b0115]. However, it should be used carefully because its negative inotropic effects can lead to cardiogenic shock [@b0120]. If an ICD fails to convert a life-threatening rhythm or in state of ICD battery exhaustion, external defibrillation can be used. Interrogating the device helps to distinguish appropriate from inappropriate therapy. If the device reveals appropriate termination of VT or VF, reversible causes such as ischemia, electrolyte imbalances, worsening heart failure, and other causes should be looked for and treated accordingly [@b0055]. Antiarrhythmic medications including amiodarone, β-blockers, and sotalol can reduce the frequency of ICD shocks [@b0125]. Programming ICDs to deliver ATP for fast VT can reduce the need for shocks. Rapid pacing often terminates VT. In PainFREE Rx II Trial, ATP was effective in terminating 229 fast VT of 284 episodes (72%). In comparison to shocks, empirical ATP for fast VT is equally safe, but highly effective, and improves quality of life [@b0130].

6. Subsequent therapy {#s0030}
=====================

6.1. Antiarrhythmics dugs {#s0035}
-------------------------

All antiarrhythmic medications except β-blockers do not improve survival when given for the primary or secondary prevention of sudden cardiac death in patients with ventricular arrhythmia. Such conclusions derived from the randomized controlled trials. However, the use of these medications is essential in some patients to control arrhythmias and improve symptoms [@b0005].

There are four classes of antiarrhythmics drugs according to Vaughan Williams classifications [@b0135]: (1) Class I fast sodium channel blockers; (2) Class II β- blockers; (3) Class III repolarization potassium current blockers; and (4) Class IV nondihydropyridines calcium channel blockers.

6.2. Monotherapy {#s0040}
----------------

### 6.2.1. β-blocker {#s0045}

Patients who experienced ES especially those who received multiple ICD shocks, will have increased sympathetic tone, which can further induce recurrent arrhythmia. β-blockers can decrease the sympathetic surge. It remains an important treatment, which can reduce the risk of recurrent VT and VF in patients with recent myocardial infarction where there is increased sympathetic activity [@b0070], [@b0140]. Propranolol antagonizes both the β1 and β2 receptors compared with metoprolol, which is β-1 selective. In addition to its peripheral β receptors blockage, propranolol and due to its lipophilic properties, it can penetrate the central nervous system and block the central and prejunctional receptors [@b0055]. Maybe due to these properties, propranolol appears to be more effective than metoprolol in terminating ES [@b0145]. Chatzidou et al. [@b0105] recently published a single-center, double-blind study of ICD 60 patients with ES. The patients were randomized to two groups and both received IV amiodarone. The propranolol group received 40 mg every 6 hours and the metoprolol group received 50 mg every 6 hours for the first 48 hours. It was shown that the termination of ventricular arrhythmias occurred significantly earlier in the propranolol group (3 hours) compared with the metoprolol group (18 hours). At the end of 24 hours, 27 of 30 patients receiving propranolol free of ventricular arrhythmias compared with 16 of 30 receiving metoprolol. Also, the period of admission to intensive care unit was significantly lower in the propranolol group (3--4 days vs. 4--6 days) [@b0105]. Moreover, propranolol seems more effective than bisoprolol. Puljević et al. [@b0150] presented cases of five patients in whom the prevention of recidivate VTs was achieved only by using propranolol. In all cases bisoprolol was used. Only after switching from bisoprolol to propranolol, VT suppressed/ICD stopped activating [@b0150]. However, β-blockers should be monitored closely in patients with severe systolic dysfunction especially in the sitting of hypotension that requires inotropic support and decompensated heart failure.

### 6.2.2. Amiodarone {#s0050}

Amiodarone is considered the most effective antiarrhythmic drug and widely used in the treatment of ES [@b0155], [@b0160]. Generally, it is safe to use unless there is contraindication such as hyperthyroidism or QT prolongation. The predominant class action is potassium channel blocker; however, it has a mixed antiarrhythmic class action [@b0095]. It is incompletely absorbed (35--65%) after oral administration. Amiodarone has a true elimination half-life of up to 60 days. Because it has a relatively slow onset of action when administered orally, usually a large loading dose is required (800--1600 mg/day in 3--4 divided doses). In the first months of therapy, arrhythmia can reoccur and should not be considered drug inefficacy. In the setting of ES, IV amiodarone (1 g/day) can be effective in termination of VT and VF during 24-hour period [@b0165]. It can suppress VT in ∼ 40% of patients within 24 hours of IV administration, even when other agents (such as mexiletine, bretylium, lidocaine, or procainamide) are ineffective [@b0170].

Amiodarone showed a higher rate of survival to hospital admission when compared with placebo or lidocaine for out-of-hospital cardiac arrest due to refractory ventricular arrhythmia [@b0175], [@b0180]. The usual doses for long-term treatment of supraventricular and ventricular arrhythmia is 200--400 mg/day, however, doses of 100 mg/day have been shown to be effective in some patients [@b0165]. The significant side effects of amiodarone limit its long-term use. They include corneal deposits (90%), photosensitivity (25--75%), pulmonary toxicity (1--17%), hyperthyroidism (0.9--2%), hypothyroidism (6%), blue-gray skin discoloration (4--9%), and liver toxicity [@b0155].

### 6.2.3. Lidocaine {#s0055}

Lidocaine class IB antiarrhythmic drug, acts as rapid sodium channel blockers binding to the receptor in a use-dependent fashion. Its effectiveness in terminating ventricular arrythmias is mostly in ischemia settings [@b0095]. In conditions other than ischemia, the effectiveness of lidocaine in terminating ventricular arrythmias range from 8% to 30%, which is considered a relatively weak antiarrhythmic effect [@b0055]. It has favorable effects in patients with normal ejection fraction and combination with amiodarone can terminate most refractory arrythmia [@b0185]. In prospective, blinded, randomized controlled trials, lidocaine was less effective than amiodarone in improving hospital admission rates after out-of-hospital cardiac arrest due to shock-refractory VF or polymorphic VT [@b0180].

### 6.2.4. Sotalol {#s0060}

Commonly Sotalol is available in a racemic mixture of [d]{.smallcaps}-isomer and [l]{.smallcaps}-isomer. [D]{.smallcaps}-isomer acts as a Class III potassium channel blocker and [L]{.smallcaps}-isomer acts as a nonselective β-blocker [@b0095]. In double-blind small trial (33 patients), results showed superiority of sotalol over lignocaine in acute termination of sustained VT [@b0190]. In optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial, it was effective in decreasing ICD shocks but it was not superior to β-blocker alone or combined β-blocker and amiodarone [@b0110]. Based on this trial and other trials, it has failed to demonstrate its superiority to β-blocker therapy in preventing recurrent ICD-shocks [@b0095]. The [d]{.smallcaps}-sotalol (pure potassium-channel blocker) was tested in a randomized controlled trial, as a primary prevention of sudden death in patients with systolic dysfunction (ejection fraction ≤40%) and previous myocardial infarction. There was an increased arrhythmic death in the [d]{.smallcaps}-sotalol-treated group and study stopped prematurely [@b0195]. Most likely, the β-blocking effect of the [l]{.smallcaps}-isomer has a protective effect [@b0090]. In view of above available data, sotalol should be considered if sustained VT were unresponsive to β-blockers [@b0115], [@b0200].

### 6.2.5. Procainamide {#s0065}

Procainamide is a Class IC agent which acts as fast sodium channel blocker. However, its active metabolite *N*-acetyl procainamide has potassium channels blockade effect as well. It can acutely terminate ventricular arrhythmias and prevent recurrences [@b0095]. Procainamide was superior to lidocaine and amiodarone in acute VT termination. Hypotension is the most limiting adverse effect that necessitates stopping the medication [@b0205], [@b0210]. The systemic side effects such as lupus-like syndrome, gastrointestinal disturbances, and autoimmune blood impairments limits its long-term use [@b0095].

### 6.2.6. Combined therapy {#s0070}

Combination therapy is usually required to treat ES [@b0215]. The most effective combination is β-blocker and amiodarone though the data are limited [@b0155]. In OPTIC study, patients were randomized to treatment for 1 year with β-blocker alone (metoprolol, carvedilol, or bisoprolol), amiodarone plus one of the aforementioned β-blockers or sotalol alone. Combination of amiodarone and a β-blocker was the most effective in reducing the number of shocks (10.3%) compared with β-blocker group (38.5%) and sotalol group (24.3%) [@b0125]. Other effective combinations includes Class III agents such as amiodarone or sotalol with a Class IC agent, flecainide [@b0200], [@b0215]. Also, it has been reported successful combination of Class III amiodarone and Class IB lidocaine or mexiletine [@b0185], [@b0220], [@b0225].

In summary, the choice of the antiarrhythmic drugs depends on the efficacy, drug-related proarrhythmic, side effects, and drug interaction.

7. Pacing {#s0075}
=========

There are reported cases of successful termination of ES by overdrive pacing which was tried after medical therapy failure [@b0230], [@b0235], [@b0240]. This is a temporary method as the ES can reoccur once the pacing is stopped. It can be used as a bridge while waiting for ischemia revascularization or trial of catheter ablation [@b0090].

8. Sedation {#s0080}
===========

Patients who experienced ES and received multiple ICD shocks, may have physical and emotional stress and enhanced sympathetic tone, that can further induce recurrent arrhythmia [@b0055]. Case reports showed that short acting anesthetics such as propofol can suppress refractory ES by inhibiting the sympathetic tone [@b0115], [@b0120].

9. Catheter ablation {#s0085}
====================

The most common form of ES is monomorphic VT and the basic mechanism of it is re-entry pathway, hence catheter ablation (CA) is an important approach to stop the storm. The current guidelines recommend CA in drug refractory arrythmia or intolerance of drugs therapy due to side effects [@b0005]. With the modern technology and increasing experience in CA, the success rate is high and the complications of the procedure are low. A meta-analysis of total of 471 ventricular arrythmias storm patients from 39 publications were collected. Successful ablation was achieved in 72% of all ventricular arrythmias and 6% patients had a recurrence of ventricular arrythmias storm. Arrhythmic storm of monomorphic VT had the higher reoccurrence rate. Overall mortality was 17% at 1.2-years follow-up with most of the deaths related to progressive heart failure (62%) [@b0015]. There are reported studies showing the superiority of CA over the medical treatment in reducing the arrythmia burden [@b0250], [@b0255], [@b0260], [@b0265] and ICD appropriate shock [@b0255], [@b0270]. Also, prophylactic CA at the time of ICD implantation in patients with history of myocardial infarction, significantly decreased ICD therapies [@b0270], [@b0275]. In VANISH trial, 259 patients with ischemic cardiomyopathy (ICM) and an ICD who had VT despite the use of antiarrhythmic drugs, were assigned to either CA with continuation of baseline antiarrhythmic drugs and escalating the antiarrhythmic drugs. There was a significantly lower rate of the composite primary outcome of death, VT storm, or appropriate ICD shock among patients undergoing CA. There was no significant between-group difference in mortality [@b0255]. The survival benefit has been reported after successful ablation of ES in single center and multicenter case series [@b0265], [@b0280] but to date no randomized control trial shows mortality benefit.

Most of the studies reported included ventricular arrythmia in patients with ischemic heart disease. In the setting of non-ischemic dilated cardiomyopathy (NIDCM), there is insufficient information on the role CA for ES [@b0265]. HELP-VT is single center nonrandomized study compared the outcomes of VT ablation in NIDCM and ICM. Two hundred and twenty-seven patients, 63 with NIDCM (34 with ES) and 164 with ICM (67 with ES), presenting with sustained VT were ablated. Complete elimination of any VT was achieved in 66.7% of NIDCM compared with 77.4% of ICM patients. The short-term outcomes were not statistically different between the two groups. At the 1-year follow-up, VT-free survival in NIDCM was 40.5% compared with 57% in ICM. The long-term outcomes were worse in NIDCM group but inability to induce VT at the end of ablation was associated with beneficial long-term outcomes [@b0285]. In a single center case series of 282 patients with NIDCM, underwent endocardial CA with an adjuvant epicardial ablation. At 60 months follow up, nearly 70% of patients had VT-free and 76% had transplant-free survival. Significant VT burden reduction was noted with repeat of ablation for VT recurrence [@b0260]. Recently, Muser et al. [@b0290] compared long-term outcomes of CA of drug refractory ES in patients with NIDCM with patients with ICM. The study included 267 consecutive patients with NIDCM (*n* = 71; ejection fraction 32 ± 14%) and ICM (*n* = 196; ejection fraction 28 ± 12%). Overall VT-free survival was 48% in NIDCM compared with 54% in ICM at 60 months. Death/transplantation-free survival was 53% in NIDCM and 64% in ICM at 60 months follow up. They concluded that CA of ES was similarly effective in patients with NIDCM compared with patients with ICM, with elimination of ES in 95% of cases and achievement of complete VT control at long-term follow-up in most patients [@b0290].

The ideal time of CA after the onset VT is not clearly defined. In a single center, 98 patients with VT and structural heart disease were studied to look for the outcome of early versus late referral for CA. Late referral was defined as two or more episodes of VT and at least 1 month apart. Thirty-six and 62 patients fit the definition of early and late referral, respectively. Overall acute procedural success was achieved in 89%. One-year VT free survival was superior in the early group. Significant reduction in amiodarone dose is another positive result of this study and best outcome seen in the early group [@b0295].

In conclusion, CA has an important role in ES management. It is superior to medical treatment in reducing arrythmia burden and ICD appropriate shock. There is growing evidence of survival benefit, however, no randomized control trial to date shows mortality benefit. It should be done early in the course of disease rather than referred late.

10. ICD implantation {#s0090}
====================

ICDs are commonly used in patients who are at high risk of sudden cardiac death. These devices do not prevent arrhythmias, and implanting an ICD is contraindicated in the acute phase of ES [@b0300]. The current guidelines recommend implantation an ICD as secondary prevention for sudden cardiac death in patients with structural heart disease who developed sustained VT whether hemodynamically stable or not provided the correctable reversible causes such as acute myocardial infarction, proarrhythmic medication effects, or electrolyte disturbances have been excluded [@b0005].

11. Refractory electrical storm {#s0095}
===============================

ES in rare situations becomes refractory to medical therapy and CA. There are alternative approaches which mainly target sympathetic blockade and modulation of the autonomic nervous system. These approaches include stellate ganglion blockade [@b0305], cardiac sympathetic denervation [@b0310], and renal artery denervation [@b0315], [@b0320]. Surgical options include postmyocardial infarction left ventricular aneurysmectomy with surgical cryoablation [@b0325] and heart transplantation [@b0265], [@b0285].

12. Conclusion {#s0100}
==============

ES is a life-threatening condition that requires prompt treatment. It carries poor outcomes despite all available intervention therapies. These therapies include rapid recognition of the condition, treatment of the reversible causes, ICD-reprogramming, antiarrhythmic drugs, sedation, and CA. The first line antiarrhythmic drugs are amiodarone and β-blocker with the superiority of the propranolol over the others. CA should be considered in drug refractory ES and patients should be referred in early course of disease.
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[^1]: ES = electrical storm; IV = intravenous.
